Tokyo, December 2, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on October 30, 2015, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
Class of shares acquired: Common stock of the Company
Total number of shares acquired: 16,000,000 shares
Aggregate amount of acquisition cost: 27,979,393,000 yen
Period of acquisition: From November 2, 2015 to December 1, 2015
Method of acquisition: Purchased on the Tokyo Stock Exchange
(Reference)
Details of the resolution at the meeting of the Board of Directors (announced on October 30, 2015)
Class of shares to be acquired: Common stock of the Company
Total number of shares to be acquired: Up to 16 million shares
(The percentage compared to the total number of shares outstanding: 0.74%)
Aggregate amount of acquisition cost: Up to 30 billion yen
Period of acquisition: From November 2, 2015 to December 18, 2015
######
For inquiries or additional information Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
distributed by |